Amarin Co. plc Given Consensus Rating of “Hold” by Analysts (NASDAQ:AMRN)
Amarin Co. plc (NASDAQ:AMRN) has earned a consensus recommendation of “Hold” from the thirteen ratings firms that are presently covering the stock, American Banking & Market News reports. Eleven analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $3.58.
Amarin Co. plc (NASDAQ:AMRN) traded up 1.81% during mid-day trading on Monday, hitting $1.6901. 611,725 shares of the company’s stock traded hands. Amarin Co. plc has a 52-week low of $1.28 and a 52-week high of $7.40. The stock’s 50-day moving average is $1.62 and its 200-day moving average is $1.65. The company’s market cap is $292.2 million.
Amarin Co. plc (NASDAQ:AMRN) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01. The company had revenue of $12.60 million for the quarter, compared to the consensus estimate of $12.86 million. The company’s revenue for the quarter was up 129.1% on a year-over-year basis. On average, analysts predict that Amarin Co. plc will post $-0.55 earnings per share for the current fiscal year.
Separately, analysts at Goldman Sachs reiterated a “neutral” rating on shares of Amarin Co. plc in a research note on Friday.
Amarin Corporation plc (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.
Receive News & Ratings for Amarin Co plc (ADR) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Co plc (ADR) and related companies with Analyst Ratings Network's FREE daily email newsletter.